Information Provided By: 
Fly News Breaks for December 6, 2016
TXMD
Dec 6, 2016 | 07:46 EDT
Jefferies analyst Matthew Andrews sees "meaningful" near-term upside in shares of TherapeuticsMD after the company reported that the top two TX-001 doses were statistically significant and clinically meaningful with "no apparent safety red flags." The analyst views the data as a "clean win" and thinks the two doses look approvable. He points out that 45M TherapeuticsMD shares are short. Andrews keeps a Buy rating on the stock with an $18 price target. The shares are up 26%, or $1.61, to $7.78 in pre-market trading.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
